Aptose Biosciences Inc. (APS.TO)
CAD 4.4
(23.94%)
CAD 4.4
(23.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -52.35 Million USD | -22.92% |
| 2022 | -42.59 Million USD | 34.92% |
| 2021 | -65.44 Million USD | -17.34% |
| 2020 | -55.77 Million USD | -107.63% |
| 2019 | -26.86 Million USD | 7.57% |
| 2018 | -29.06 Million USD | -147.18% |
| 2017 | -11.75 Million USD | 15.03% |
| 2016 | -13.83 Million USD | -21.3% |
| 2015 | -11.4 Million USD | 3.01% |
| 2014 | -11.76 Million USD | -33.9% |
| 2013 | -8.78 Million USD | -62.87% |
| 2012 | -5.39 Million USD | -20.82% |
| 2011 | -4.46 Million USD | 12.46% |
| 2010 | -5.09 Million USD | 67.57% |
| 2009 | -15.72 Million USD | -190.0% |
| 2008 | -5.42 Million USD | 66.51% |
| 2007 | -16.18 Million USD | -139.75% |
| 2006 | -6.75 Million USD | 53.01% |
| 2005 | -14.36 Million USD | -181.19% |
| 2004 | 17.69 Million USD | 176.45% |
| 2003 | -23.15 Million USD | -277.96% |
| 2002 | 13 Million USD | 228.4% |
| 2001 | -10.13 Million USD | 14.0% |
| 2000 | -11.77 Million USD | -93.11% |
| 1999 | -6.1 Million USD | -83.56% |
| 1998 | -3.32 Million USD | 1.21% |
| 1997 | -3.36 Million USD | 3.41% |
| 1996 | -3.48 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.75 Million USD | 19.53% |
| 2024 Q2 | -7.34 Million USD | 24.74% |
| 2023 FY | -52.35 Million USD | -22.92% |
| 2023 Q1 | -14.22 Million USD | -36.73% |
| 2023 Q2 | -14.44 Million USD | -1.56% |
| 2023 Q3 | -11.68 Million USD | 19.14% |
| 2023 Q4 | -12.12 Million USD | -3.81% |
| 2022 FY | -42.59 Million USD | 34.92% |
| 2022 Q4 | -10.4 Million USD | -3.83% |
| 2022 Q1 | -11.49 Million USD | 52.78% |
| 2022 Q2 | -10.67 Million USD | 7.19% |
| 2022 Q3 | -10.02 Million USD | 6.08% |
| 2021 Q3 | -11.36 Million USD | 15.72% |
| 2021 Q4 | -24.35 Million USD | -114.29% |
| 2021 Q2 | -13.48 Million USD | 17.03% |
| 2021 Q1 | -16.25 Million USD | -10.04% |
| 2021 FY | -65.44 Million USD | -17.34% |
| 2020 Q1 | -11.81 Million USD | -49.76% |
| 2020 Q2 | -15.89 Million USD | -34.5% |
| 2020 Q4 | -14.76 Million USD | -11.1% |
| 2020 Q3 | -13.29 Million USD | 16.38% |
| 2020 FY | -55.77 Million USD | -107.63% |
| 2019 Q3 | -7.02 Million USD | -10.67% |
| 2019 Q2 | -6.34 Million USD | -13.28% |
| 2019 Q1 | -5.6 Million USD | 11.09% |
| 2019 FY | -26.86 Million USD | 7.57% |
| 2019 Q4 | -7.89 Million USD | -12.37% |
| 2018 Q3 | -5.61 Million USD | 45.64% |
| 2018 FY | -29.06 Million USD | -147.18% |
| 2018 Q1 | -6.82 Million USD | -151.26% |
| 2018 Q2 | -10.32 Million USD | -51.22% |
| 2018 Q4 | -6.3 Million USD | -12.3% |
| 2017 Q3 | -2.78 Million USD | -11.79% |
| 2017 FY | -11.75 Million USD | 15.03% |
| 2017 Q1 | -3.28 Million USD | -8.73% |
| 2017 Q2 | -2.49 Million USD | 24.21% |
| 2017 Q4 | -2.71 Million USD | 2.48% |
| 2016 FY | -13.83 Million USD | -21.3% |
| 2016 Q4 | -3.02 Million USD | 4.49% |
| 2016 Q3 | -3.16 Million USD | 26.89% |
| 2016 Q2 | -4.33 Million USD | -15.29% |
| 2016 Q1 | -3.75 Million USD | -10.12% |
| 2015 FY | -11.4 Million USD | 3.01% |
| 2015 Q1 | -2.79 Million USD | 8.79% |
| 2015 Q4 | -3.41 Million USD | -17.01% |
| 2015 Q3 | -2.91 Million USD | 3.24% |
| 2015 Q2 | -3.01 Million USD | -7.63% |
| 2014 FY | -11.76 Million USD | -33.9% |
| 2014 Q4 | -3.06 Million USD | -79714.75% |
| 2014 Q3 | -3845.50 USD | 99.9% |
| 2014 Q2 | -3.82 Million USD | -80.49% |
| 2014 Q1 | -2.12 Million USD | 17.45% |
| 2013 FY | -8.78 Million USD | -62.87% |
| 2013 Q4 | -2.56 Million USD | -154.35% |
| 2013 Q2 | -1.24 Million USD | 6.74% |
| 2013 Q3 | -1.01 Million USD | 19.11% |
| 2013 Q1 | -1.33 Million USD | 17.53% |
| 2012 FY | -5.39 Million USD | -20.82% |
| 2012 Q1 | -1.02 Million USD | 27.74% |
| 2012 Q2 | -839.02 Thousand USD | 18.38% |
| 2012 Q3 | -1.27 Million USD | -51.59% |
| 2012 Q4 | -1.62 Million USD | -27.67% |
| 2011 Q2 | -1.07 Million USD | 34.04% |
| 2011 Q1 | -1.62 Million USD | -36.5% |
| 2011 Q3 | -1.14 Million USD | -7.07% |
| 2011 Q4 | -1.42 Million USD | -24.12% |
| 2011 FY | -4.46 Million USD | 12.46% |
| 2010 Q3 | -1.07 Million USD | 36.06% |
| 2010 FY | -5.09 Million USD | 67.57% |
| 2010 Q1 | -1.27 Million USD | -7.84% |
| 2010 Q2 | -1.68 Million USD | -31.51% |
| 2010 Q4 | -1.18 Million USD | -10.48% |
| 2009 FY | -15.72 Million USD | -190.0% |
| 2009 Q4 | -1.18 Million USD | 89.24% |
| 2009 Q3 | -11.02 Million USD | -710.36% |
| 2009 Q2 | -1.36 Million USD | -10.82% |
| 2009 Q1 | -1.22 Million USD | -11.72% |
| 2008 Q1 | -3.18 Million USD | -21.81% |
| 2008 Q2 | -9.07 Million USD | -185.08% |
| 2008 FY | -5.42 Million USD | 66.51% |
| 2008 Q3 | -2.09 Million USD | 76.92% |
| 2008 Q4 | -1.09 Million USD | 47.53% |
| 2007 Q1 | -1.23 Million USD | 45.01% |
| 2007 Q4 | -2.61 Million USD | 63.37% |
| 2007 Q3 | -7.13 Million USD | -379.58% |
| 2007 Q2 | -1.48 Million USD | -20.59% |
| 2007 FY | -16.18 Million USD | -139.75% |
| 2006 Q1 | -3.12 Million USD | 21.24% |
| 2006 FY | -6.75 Million USD | 53.01% |
| 2006 Q4 | -2.24 Million USD | -16.05% |
| 2006 Q3 | -1.93 Million USD | 23.73% |
| 2006 Q2 | -2.53 Million USD | 18.81% |
| 2005 Q2 | 31.74 Million USD | 880.07% |
| 2005 Q1 | -4.06 Million USD | 18.45% |
| 2005 Q4 | -3.96 Million USD | 11.0% |
| 2005 Q3 | -4.45 Million USD | -114.02% |
| 2005 FY | -14.36 Million USD | -181.19% |
| 2004 Q2 | -5.66 Million USD | 10.67% |
| 2004 Q4 | -4.99 Million USD | -2.53% |
| 2004 Q3 | -4.86 Million USD | 14.05% |
| 2004 Q1 | -6.33 Million USD | -30.37% |
| 2004 FY | 17.69 Million USD | 176.45% |
| 2003 Q3 | -6.18 Million USD | -237.76% |
| 2003 Q4 | -4.86 Million USD | 21.4% |
| 2003 Q2 | 4.49 Million USD | 64.11% |
| 2003 Q1 | 2.73 Million USD | 199.96% |
| 2003 FY | -23.15 Million USD | -277.96% |
| 2002 Q4 | -2.73 Million USD | 4.07% |
| 2002 FY | 13 Million USD | 228.4% |
| 2002 Q1 | -2.2 Million USD | 7.95% |
| 2002 Q2 | -2.99 Million USD | -35.52% |
| 2002 Q3 | -2.85 Million USD | 4.65% |
| 2001 Q4 | -2.39 Million USD | -1.66% |
| 2001 FY | -10.13 Million USD | 14.0% |
| 2001 Q3 | -2.35 Million USD | 47.0% |
| 2001 Q2 | -4.45 Million USD | -100.09% |
| 2001 Q1 | -2.22 Million USD | 24.31% |
| 2000 Q1 | -1.17 Million USD | -72.52% |
| 2000 Q3 | -2.23 Million USD | 39.52% |
| 2000 FY | -11.77 Million USD | -93.11% |
| 2000 Q2 | -3.68 Million USD | -214.8% |
| 2000 Q4 | -2.94 Million USD | -31.83% |
| 1999 Q2 | -538.96 Thousand USD | 49.19% |
| 1999 Q1 | -1.06 Million USD | -62.92% |
| 1999 Q4 | -679.09 Thousand USD | -102.99% |
| 1999 FY | -6.1 Million USD | -83.56% |
| 1999 Q3 | -334.54 Thousand USD | 37.93% |
| 1998 Q1 | -1.05 Million USD | 6.12% |
| 1998 Q2 | -412.9 Thousand USD | 60.82% |
| 1998 Q4 | -651.04 Thousand USD | 26.51% |
| 1998 Q3 | -885.85 Thousand USD | -114.54% |
| 1998 FY | -3.32 Million USD | 1.21% |
| 1997 Q4 | -1.12 Million USD | -55.94% |
| 1997 Q3 | -719.94 Thousand USD | 0.0% |
| 1997 FY | -3.36 Million USD | 3.41% |
| 1996 FY | -3.48 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -8.05 Million CAD | -550.37% |
| Eupraxia Pharmaceuticals Inc. | -36.89 Million CAD | -41.899% |
| Helix BioPharma Corp. | -9.37 Million CAD | -458.702% |
| Microbix Biosystems Inc. | -2.73 Million CAD | -1813.294% |
| Medicenna Therapeutics Corp. | -19.66 Million CAD | -166.267% |
| Satellos Bioscience Inc. | -15.46 Million CAD | -238.589% |
| Oncolytics Biotech Inc. | -33.79 Million CAD | -54.941% |
| Sernova Corp. | -41.13 Million CAD | -27.292% |